Mobocertinib is a widely used drug in the treatment of lung cancer, and its efficacy has been widely recognized. However, in order to ensure that patients are able to use Mobocertinib safely and effectively, proper medication guidelines are essential. This article will present guidelines for the use of Mobocertinib to help patients and physicians better understand and manage the use of this medication.
What are the dosing guidelines for Mobocertinib?
The following are guidelines for the use of Mobocertinib:
Patient selection
Only for patients with a confirmed diagnosis of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Recommended Dosage
Oral once daily at a recommended dose of 160 mg at the same time each day, with or without food.
Swallow Mobocertinib(Exkivity) whole without opening, chewing, or dissolving the contents of the capsule.
If you miss a dose for more than 6 hours, skip the dose and take the next dose at the normal time the next day according to the medication schedule, and if vomiting occurs after taking it, you do not need to make up the dose, and take the next dose at the normal time the next day according to the medication schedule.
Dose adjustment for co-administration with moderate CYP3A inhibitors
Combination of Mobocertinib(Exkivity) with moderate CYP3A inhibitors should be avoided. If combination with a moderate CYP3A inhibitor cannot be avoided, reduce the dose of Mobocertinib by approximately 50% (i.e., from 160 mg to 80mg, 120mg to 40mg, or 80mg to 40mg) and monitor the patient's QTc interval more frequently.
After stopping the use of moderate CYP3A inhibitors for 3-5 elimination half-lives, resume the drug according to the dose of Mobocertinib before starting the use of moderate CYP3A inhibitors. More information on medications? Click here for a free online consultation
Who should pay attention when taking the drug?
The following groups of people need to be aware of when using Mobocertinib:
Pregnant women
Pregnant women are advised not to use Mobocertinib.
Lactating women
Lactating women are advised not to breastfeed during treatment with Mobocertinib and for 1 month after the last dose.
Males and females of reproductive potential
Women of reproductive potential are advised to use effective non-hormonal contraceptives during treatment with Mobocertinib and for 1 month after the last dose. At the same time, men with female partners of reproductive potential are advised to use effective contraception during treatment with Mobocertinib and for 1 week after the last dose.
Pediatric patients
safety and efficacy in pediatric patients have not been established, so the safety of Mobocertinib in pediatric patients is uncertain.
Older patients
there is no significant difference, but Mobocertinib should still be used under physician supervision.
When using Mobocertinib, it is necessary to follow your doctor's advice and pay attention to the side effects and interactions of the drug to ensure the safe and effective use of the drug. At the same time, it is also necessary to pay attention to the use and dosage of drugs to avoid overdose or insufficiency.
Mobocertinib is an effective anti-cancer drug, but its use requires caution. By following the right medication guidelines, patients and doctors can better control side effects and maximize their anti-cancer effects.
Before using Mobocertinib, patients should consult their doctor for detailed instructions on medication and follow their doctor's recommendations for treatment. Only under the supervision of a doctor can the best therapeutic effect be obtained with rational medication and minimize the potential risks and side effects.
